Role of 18F-FDG PET/CT in the Evaluation of Cavernous Sinus Syndrome: a Pilot Study

Cavernous sinus syndrome (CSS) can be caused by a wide range of inflammatory, malignant, benign, vascular and miscellaneous disorders. Even after modern advances, reaching the final etiological diagnosis remains a challenge in CSS. This study is planned to determine the role and incremental value of 18F-FDG PET/CT in characterising different cavernous sinus pathologies based on their metabolic activity and detecting extracranial involvement.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Cavernous Sinus Syndrome Brain Diseases Cavernous Sinus Lesions Cavernous Sinus Meningioma Cavernous Sinus Syndromes Central Nervous System Diseases Cranial Nerve Diseases Eye Diseases Nervous System Diseases Neurologic Manifestations Ocular Motility Disorders Ophthalmoplegia Paralysis Pathological Conditions, Signs and Symptoms Signs and Symptoms

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Post Graduate Institute of Medical Education and Research

Chandigarh, 160012, India

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Patients with age greater than or equal to 18 years,
with newly diagnosed CSS,
lesion seen on MRI in the CS, and
willing to give written informed consent.

Exclusion criteria

Pregnant and lactating patients
Patients already being treated (including steroids)

Treatment and study plan

FDG radiotracer

Diagnostic Test

Pilot study evaluating the role of FDG PET/CT in Cavernous sinus syndrome

Other names: FDG PET/CT

Primary outcomes

SUVmax of the cavernous sinus lesions on FDG PET/CT

Time frame: From enrollment to the establishment of final diagnosis upto a period of three months

Standardized uptake value (SUV) will be calculated by drawing region of interest (ROI) in the cavernous sinus region both on the whole body and the dedicated brain image, while carefully excluding normal brain activity. If lesions in the bilateral cavernous sinuses will be present, SUVmax of both the lesions will be noted.
Number of patients with extracranial sites of involvement on FDG PET/CT

Time frame: From enrollment to the establishment of final diagnosis upto 3 months

Sponsors and collaborators

Lead sponsor

Post Graduate Institute of Medical Education and Research, Chandigarh

Other

Registry information

Important dates

Study start: 2022
Primary completion: 2023
Study completion: 2024
First posted: Dec 6, 2024
Registry last updated: Dec 6, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed